9.85
price down icon3.81%   -0.39
after-market Dopo l'orario di chiusura: 9.85
loading

Pavmed Inc Borsa (PAVM) Ultime notizie

pulisher
05:12 AM

Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus

05:12 AM
pulisher
12:30 PM

Big Money Moves: Whats next for PAVmed Inc stockBuy Signal & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

12:30 PM
pulisher
Apr 04, 2026

PAVM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026
pulisher
Apr 03, 2026

PAVmed (PAVM) CEO Lishan Aklog awarded 350,000 restricted shares vesting 2029 - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Craig Kallman (PAVM) holds 384,616 shares, a 6.0% stake in PAVmed - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

PAVmed (PAVM) CFO awarded 180,000 restricted shares vesting 2029 - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Director at PAVmed (PAVM) receives 13,930 restricted stock shares - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

PAVmed (PAVM) director Timothy Baxter receives 13,930 restricted shares vesting in 2029 - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Restricted stock grant boosts PAVmed (PAVM) director’s holdings - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

PAVmed (PAVM) director gets 13,930-share restricted stock grant - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Restricted stock award boosts PAVmed (NASDAQ: PAVM) director stake - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Tasso Partners and Dana Carrera disclose 14.3% stake in PAVmed (PAVM) - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

PAVmed (PAVM) general counsel receives 110,000-share restricted award - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

PAVmed (PAVM) COO receives 110,000-share restricted stock grant vesting 2029 - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Lucid Diagnostics Inc. (LUCD) stock price, news, quote and history - Yahoo Finance UK

Apr 03, 2026
pulisher
Apr 03, 2026

PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio - Bitget

Apr 03, 2026
pulisher
Apr 02, 2026

PAVmed appoints Joseph Virgilio as medical device chief By Investing.com - Investing.com Australia

Apr 02, 2026
pulisher
Apr 02, 2026

PAVmed raises $45 million, restructures capital to eliminate convertible debt - Investing.com

Apr 02, 2026
pulisher
Apr 02, 2026

PAVmed: Octeris, Inc. Subsidiary Formed to Advance Endoscopic Esophageal Imaging Tech Recently Licensed From Duke University >PAVM - Moomoo

Apr 02, 2026
pulisher
Apr 02, 2026

PAVmed appoints Joseph Virgilio as medical device chief - Investing.com

Apr 02, 2026
pulisher
Apr 02, 2026

PAVM Technical Analysis | Trend, Signals & Chart Patterns | PAVMED INC (NASDAQ:PAVM) - ChartMill

Apr 02, 2026
pulisher
Apr 01, 2026

PAVmed Inc. (NASDAQ:PAVM) Q4 2025 Earnings Call Transcript - Insider Monkey

Apr 01, 2026
pulisher
Apr 01, 2026

PAVmed raises $45 million, restructures capital to eliminate convertible debt By Investing.com - Investing.com India

Apr 01, 2026
pulisher
Mar 31, 2026

Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Cuts Target Price to $16 - Moomoo

Mar 31, 2026
pulisher
Mar 31, 2026

PAVmed Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 31, 2026
pulisher
Mar 31, 2026

Fundamentals Check: Is PAVmed Inc a potential multi baggerWeekly Profit Recap & High Conviction Buy Zone Picks - baoquankhu1.vn

Mar 31, 2026
pulisher
Mar 31, 2026

PAVmed completes $45M financing, eliminates convertible debt By Investing.com - Investing.com Australia

Mar 31, 2026
pulisher
Mar 30, 2026

PAVmed (PAVM) upgraded to buy: Here's what you should know - msn.com

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed Inc (PAVM) Q4 2025 Earnings Call Highlights: Strategic Re - GuruFocus

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-03-30 - Seeking Alpha

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Mar 30, 2026
pulisher
Mar 30, 2026

PAVM: Q4 2025 featured diagnostic revenue growth, a VA contract, and improved non-GAAP loss per share - TradingView

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed Reports 2025 Financial Results, Strengthens Capital Structure, and Expands Medical Device Portfolio Under New Leadership - Minichart

Mar 30, 2026
pulisher
Mar 30, 2026

Earnings call transcript: PAVmed Q4 2025 shows restructuring gains By Investing.com - Investing.com India

Mar 30, 2026
pulisher
Mar 30, 2026

Earnings call transcript: PAVmed Q4 2025 shows restructuring gains - Investing.com

Mar 30, 2026
pulisher
Mar 30, 2026

PAVM: Restructuring and growth initiatives drive commercial momentum and financial stability - TradingView

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed Reports Q4 2025 Financial Results with Key Metrics - Intellectia AI

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed Reports 2025 Results, Strengthens Balance Sheet - TipRanks

Mar 30, 2026
pulisher
Mar 30, 2026

Q4 2025 PAVmed Inc Earnings Call Transcript - GuruFocus

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed completes $45M financing, eliminates convertible debt - Investing.com

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed (NASDAQ: PAVM) overhauls capital structure and reports 2025 results - Stock Titan

Mar 30, 2026
pulisher
Mar 30, 2026

PAVM: Q4 2025 featured capital restructuring, expanded diagnostics, and improved financials - TradingView

Mar 30, 2026
pulisher
Mar 30, 2026

PAVmed Q4 2025 Earnings Call Transcript - MarketBeat

Mar 30, 2026
pulisher
Mar 29, 2026

PAVmed to Announce Q4 Earnings on March 30 - Intellectia AI

Mar 29, 2026
pulisher
Mar 29, 2026

PAVmed Q2 2025 Earnings Preview - MSN

Mar 29, 2026
pulisher
Mar 28, 2026

PAVmed Inc. 8-K Filing Details: Company Information, Nasdaq Listing, and 2026 Shareholder Meeting Results - Minichart

Mar 28, 2026
pulisher
Mar 28, 2026

PAVmed Inc. 2025 Annual Report: Financials, Risk Factors, and Corporate Governance Overview - Minichart

Mar 28, 2026
pulisher
Mar 28, 2026

Bear Alert: Whats next for PAVmed Inc stock2026 Sector Moves & Safe Capital Growth Tips - baoquankhu1.vn

Mar 28, 2026
pulisher
Mar 27, 2026

PAVmed's Capital Cleanup Hides High-Reward Catalyst for Patient Biotech Investors - Bitget

Mar 27, 2026
pulisher
Mar 27, 2026

PAVmed Shareholders Approve Equity Issuance and Governance Changes - TipRanks

Mar 27, 2026
pulisher
Mar 27, 2026

PAVmed shareholders approve stock issuance, charter amendment, and equity plan changes - Investing.com UK

Mar 27, 2026
pulisher
Mar 27, 2026

PAVmed (NASDAQ: PAVM) holders approve stock issuances and expand equity plan - stocktitan.net

Mar 27, 2026
pulisher
Mar 27, 2026

PAVmed 2025 10-K: Revenue $0.1M; loss before noncontrolling interests ~$2.5M - TradingView

Mar 27, 2026
pulisher
Mar 27, 2026

PAVmed (PAVM) outlines going concern risk, Nasdaq compliance and growth plans - stocktitan.net

Mar 27, 2026
pulisher
Mar 27, 2026

PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener

Mar 27, 2026
pulisher
Mar 27, 2026

PAVmed Inc Extraordinary Shareholders Meeting Transcript - GuruFocus

Mar 27, 2026
pulisher
Mar 27, 2026

What To Expect From PAVmed Inc (PAVM) Q4 2025 Earnings - GuruFocus

Mar 27, 2026
pulisher
Mar 27, 2026

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - StreetInsider

Mar 27, 2026
pulisher
Mar 27, 2026

[EFFECT] Lucid Diagnostics Inc. SEC Filing - Stock Titan

Mar 27, 2026
pulisher
Mar 27, 2026

Lucid Diagnostics reports Q4 revenue of $1.5M, VA contract By Investing.com - Investing.com South Africa

Mar 27, 2026
pulisher
Mar 26, 2026

Lucid Diagnostics Reports 2025 Financial Results, Expands EsoGuard Access with VA Contract and Positive Real-World Data - Minichart

Mar 26, 2026
pulisher
Mar 26, 2026

Lucid Diagnostics Reports Q4 2025 Results, Highlights VA Contract - TipRanks

Mar 26, 2026
ZBH ZBH
$90.89
price down icon 0.15%
STE STE
$218.71
price down icon 0.56%
$62.22
price down icon 0.24%
PHG PHG
$27.11
price down icon 0.66%
$70.35
price down icon 2.26%
EW EW
$81.05
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):